Stocks · News reference
UBS Maintains Neutral on Oscar Health, Raises Price Target to $36
UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $26 to $36.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oscar Health Q3 2026 Earnings Call Transcript
Oscar Health (NYSE:OSCR) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by Benzinga APIs. For
Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook
Oscar Health reported its financial results for the third quarter ended September 30, 2026, and updated its full-year 2026 financial outlook.
8-K filing — Oscar Health, Inc. (OSCR)
Filed: 2026-11-05 AccNo: 0001568651-26-000082 Size: 528 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Oscar Health Receives Approval for 2027 ACA Rate Increases in Missouri
Missouri regulators have finalized 2027 health insurance rate increases for Affordable Care Act marketplace plans, with Oscar Health reporting a 15% average rate adjustment in the St. Louis area.
Oscar Health Seeks to Void Court Order for Cancer Medication Coverage
Oscar Health has requested that a Miami-Dade court void a previous order requiring the company to cover a $48,500 cancer medication for a patient, arguing that the patient's medical circumstances have changed.